Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Efficacy, Tolerability, and Safety of Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Disorder: An Open-Label Extension Trial
EF 2022-23
Résumé
Bipolar depression (BD) is a debilitating mental illness associated with depressed mood, suicidal ideation, and functional impairment. Around one-quarter to one-third of patients with BD who do not respond to commonly prescribed antidepressants are diagnosed with treatment-resistant BD (TRBD).
Initially approved as an anesthetic, ketamine has been studied as a potential treatment for mood disorders, including TRBD, and has been shown to reduce depressive symptoms and suicidal ideation in several trials. However, ketamine’s effects are short-lasting, with most patients relapsing into depression after two to three weeks. A potential method for relapse prevention would be to administer ketamine over the long-term, but there is a lack of data on the effectiveness of long-term ketamine administration in patients with TRBD.
In the proposed research, BD patients who have shown an antidepressant response to intravenous (IV) ketamine infusions in a previous trial will now enter a 12-week trial where IV ketamine will be administered once every two weeks. The research aims to primarily determine whether these maintenance infusions will sustain the antidepressant effects over a longer time period, determine the safety of ketamine, and observe changes in suicidality, cognition, and quality-of-life. Based on the limited research with TRBD patients, we hypothesize that ketamine will maintain the antidepressant effects that patients previously experienced.
Following infusions, mood assessments and cognitive questionnaires will be administered to measure the severity of depression and determine changes in cognition and quality-of-life. This project will improve the understanding of ketamine’s role in preventing depression relapse and ultimately provide relief for TRBD patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486405
Name
Haikazian Sipan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Efficacy, Tolerability, and Safety of Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Disorder: An Open-Label Extension Trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bipolar Depression; Glutamatergic Agent; Ketamine; Mental Disorders; Open-Label Trial
Abstract
Bipolar depression (BD) is a debilitating mental illness associated with depressed mood, suicidal ideation, and functional impairment. Around one-quarter to one-third of patients with BD who do not respond to commonly prescribed antidepressants are diagnosed with treatment-resistant BD (TRBD).
Initially approved as an anesthetic, ketamine has been studied as a potential treatment for mood disorders, including TRBD, and has been shown to reduce depressive symptoms and suicidal ideation in several trials. However, ketamine’s effects are short-lasting, with most patients relapsing into depression after two to three weeks. A potential method for relapse prevention would be to administer ketamine over the long-term, but there is a lack of data on the effectiveness of long-term ketamine administration in patients with TRBD.
In the proposed research, BD patients who have shown an antidepressant response to intravenous (IV) ketamine infusions in a previous trial will now enter a 12-week trial where IV ketamine will be administered once every two weeks. The research aims to primarily determine whether these maintenance infusions will sustain the antidepressant effects over a longer time period, determine the safety of ketamine, and observe changes in suicidality, cognition, and quality-of-life. Based on the limited research with TRBD patients, we hypothesize that ketamine will maintain the antidepressant effects that patients previously experienced.
Following infusions, mood assessments and cognitive questionnaires will be administered to measure the severity of depression and determine changes in cognition and quality-of-life. This project will improve the understanding of ketamine’s role in preventing depression relapse and ultimately provide relief for TRBD patients.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Haikazian, Sipan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~